Lindbrook Capital, LLC Arcellx, Inc. Call Options Transaction History
Lindbrook Capital, LLC
- $1.06 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACLX
# of Institutions
214Shares Held
48.8MCall Options Held
764KPut Options Held
296K-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$287 Million15.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.99MShares$255 Million0.0% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$239 Million23.3% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$225 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.04MShares$194 Million4.14% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.8B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...